key: cord-0936484-jx787cpx
authors: Patel, Tejas K.; Patel, Parvati B.; Barvaliya, Manish; Saurabh, Manoj Kumar; Bhalla, Hira Lal; Khosla, Prem Parkash
title: Efficacy and safety of Lopinavir-Ritonavir in COVID-19: A Systematic Review of randomized controlled trials
date: 2021-04-20
journal: J Infect Public Health
DOI: 10.1016/j.jiph.2021.03.015
sha: 2fa2c5fc0f9a4fe7cb19da5d35b9245c8c327809
doc_id: 936484
cord_uid: jx787cpx

BACKGROUND: Lopinavir-ritonavir is a repurposed drug for coronavirus disease-2019 (COVID-19). In this study, a pooled effect of lopinavir-ritonavir on mortality, virological cure, radiological improvement and safety profile in COVID-19 patients has been evaluated. METHODS: The databases were searched for comparative randomized controlled studies evaluating the efficacy and/or safety of lopinavir-ritonavir in COVID-19 patients. The mortality outcome was pooled as a risk difference (RD) with 95% CI. The virological cure, radiological improvement and adverse events were pooled as risk ratio (RR) with 95% CI. All outcomes were pooled using the Mantle-Hanzle method random effect model. The heterogeneity was assessed using the I(2) test. RESULTS: Out of 82 full text assessed, seven studies were included in the analysis. The included studies had five different control interventions: supportive care (n = 4), umifenovir (arbidol) (n = 2), navaferon (recombinant anti-tumour and anti-virus protein) (n = 1), lopinavir-ritonavir + novaferon (n = 1) and lopinavir-ritonavir + interferon beta 1b + ribavirin (n = 1). Lopinavir-ritonavir group did not show significant difference in mortality [RD: 0.00 (95% CI: -0.01, 0.02), I(2) = 0], virological cure [RR: 1.06 (95% CI: 0.85, 1.31), I(2) = 0%], radiological improvement [RR: 0.81 (95% CI: 0.62, 1.05)] and adverse events [RR: 2.59 (95% CI: 0.17, 38.90), I(2)= 75%] than supportive care. Similarly, no difference was observed for any efficacy outcomes between lopinavir-ritonavir and other control interventions. We observed significantly high risk of adverse events with lopinavir-ritonavir as compared to umifenovir [RR: 2.96 (95% CI: 1.42-6.18); I(2) = 0%]. CONCLUSION: There is no benefit of the addition of lopinavir-ritonavir to the standard care in COVID-19 patients.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) belongs to the beta Coronaviridae family, like SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) [1] and is responsible for the current pandemic of Corona Virus Disease 2019 . After infection, patients present with mild to severe symptoms, including fever, cough, sore throat, rhinorrhea, severe pneumonia, and septic shock. Few patients infected with SARS-CoV-2 develop acute respiratory distress syndrome, leading to a high rate of admission to intensive care units and ultimately death in severe cases [2] , [3] . The clinical presentation of COVID-19 greatly resembles SARS-CoV infection [3] .

Currently, no antiviral treatment is proven to be effective in SARS-CoV-2 infection. Optimized supportive care remains the mainstay of therapy for it. Therefore, identifying drug treatment options as soon as possible is critical for the response to the COVID-19 outbreak.

The Lopinavir-ritonavir combination is one of the repurposed drugs currently used in the treatment of COVID-19. They are protease inhibitors used for treating HIV infection. Both these drugs are suggested to inhibit SARS-CoV 3C-like protease enzyme [1] . The protease is considered a key enzyme in coronavirus polyprotein processing [4] . In vitro study of Choy et al. suggested that lopinavir could achieve the therapeutic working concentration of 26.63 μM against SARS-CoV-2 in Vero E6 cells [5] . However, ritonavir alone did not show the in-vitro activity against SARS-CoV-2. Another in-vitro study by Kang et al observed significant antiviral activity of a combination of lopinavir-ritonavir against SARS-CoV-2 [6] . A recent animal study by Park et al did not show in-vivo efficacy of lopinavir-ritonavir in SARS-CoV-2 infection in the ferret model [7] . The current use of lopinavir-ritonavir is mainly based on the experience of the use of lopinavir-ritonavir in SARS and MERS. A systematic review of lopinavir-ritonavir J o u r n a l P r e -p r o o f therapy in patients of SARS and MERS suggested better clinical outcomes and a lower risk of ARDS or death. However, the evidence was mainly based on case reports and retrospective caseseries [8] .

The literature for the use of lopinavir-ritonavir in the treatment of COVID-19 is now available in the form of randomized controlled trials. So, this systematic review aimed to find out the efficacy and safety outcomes in COVID-19 patients treated with lopinavir-ritonavir combination through the meta-analytic summary.

J o u r n a l P r e -p r o o f

Two investigators independently systematically searched the databases: PubMed, medrxiv.org, biorxib.org, mediterranee-infection.com/pre-prints-ihu, Google Scholar and CNKI. The search terms were: (Lopinavir AND Ritonavir) AND (COVID-19 OR coronavirus OR SARS-CoV-2).

The last search was run on 27 th December 2020. There were no language and time restriction to include the published articles. Titles, abstracts and full articles (if required) were assessed for deciding the eligibility of retrieved articles. Any disagreements were resolved by discussion and consensus among the authors. 

Use of lopinavir-ritonavir irrespective of dose and duration of therapy was considered. All treatment modalities including supportive care or placebo were considered as the control arm.

The interventions as an add on to the lopinavir-ritonavir treatment arm were analyzed separately.

Two investigators assessed the methodological quality of the included randomized studies as per revised Cochrane "risk of bias assessment tool for the randomized controlled clinical trials (ROB-II)" [9] . Each study was assessed for the possibility of risk of bias in the following five domains: a process of randomization, deviations from the intended interventions, missing outcome data, outcome measurement and selection of the reported results. Each domain was categorized into low, high or having some concerns in the risk of bias assessment [9] . Any disagreements were resolved by discussion and consensus among the authors.

The following data were extracted in a Microsoft Excel sheet, 2016: first author, publication

year, study design, study site, baseline data of study population in treatment arms (age, gender, the severity of the disease, days of illness to start of treatment), lopinavir-ritonavir and comparator interventions (dosage, duration and route of administration), supportive care and efficacy (mortality, virological cure, radiological improvement in treatment arms), safety (adverse events) data and intention to treat analysis. The data were cross-checked to ensure the accuracy of extraction.

J o u r n a l P r e -p r o o f Mortality, virological cure and radiological improvement between patients who received lopinavir-ritonavir and control interventions at the end of the study period were analysed based on the type of control interventions. At the end of study period data were used in case of multiple time-point estimations of outcomes in the included studies. The intention to treat the study population was used to estimate the efficacy outcomes.

The safety outcomes were the number of adverse events between lopinavir-ritonavir and control interventions at the end of the study period. Adverse events were analysed based on the type of control interventions using the safety population. All patients who received lopinavir-ritonavir and control interventions irrespective of per-protocol dose and duration were considered as a safety population.

All outcomes were the dichotomous variables. The mortality outcome was summarized as a risk difference (RD) with 95% CI. The virological cure, radiological improvement and adverse events were summarized as risk ratio (RR) with 95% CI. All outcomes were pooled using the Mantle-Hanzle method. The fixed effect or random model was used to estimate the meta-analytic summary. In case of substantial heterogeneity, the random effect model was preferred over the fixed effect model. The heterogeneity was assessed using the I 2 test. The heterogeneity was considered as 25% -low, 50% -moderate and 75% -high. The publication bias was assessed visually through a 'funnel plot'. It was plotted using [log (OR)] and standard error of efficacy and safety outcomes.

The sensitivity analyses of efficacy and safety outcomes were performed based on the risk of bias assessment as per ROB-II tool. The meta-analytic summary was estimated by excluding studies showing 'some concern' or 'high' risk of bias.

The meta-analysis was performed through 'Review manager software version 5.3'.

J o u r n a l P r e -p r o o f 3. Results

From the literature search, we retrieved 2188 references and assessed 82 full-text articles. A total of 7 randomized controlled studies fulfilling the selection criteria were included in the analysis ( Figure 1 ). Among 7 included studies, there were total 9 control interventions with five different modalities: supportive care (n=4), umifenovir (n=2), navaferon (n=1), lopinavir-ritonavir+novaferon (n=1) and lopinavir-ritonavir+interferon beta 1b+ribavirin (n=1).

Umifenovir is a generic name of arbidol. It is used as an antiviral drug for influenza in Russia and China. Novaferon is a recombinant anti-tumour and anti-virus protein, which is developed using cDNA sequences of 12 human interferon subtypes. Its nucleotide sequences are 89% homologous to human interferon α-2b. The general characteristics of all included studies are presented in Table1 [10] , [11] , [12] , [13] , [14] , [15] , [16] . Participants in both groups were comparable at baseline for the age, gender, clinical features, laboratory values, comorbid conditions, National Early Warning Score 2 (NEWS2), days from illness to randomization and severity status. NEWS2 at admission is calculated based on respiration rate, oxygen saturation, systolic blood pressure, pulse rate and level of consciousness.

Each parameter is scored from 0 to 3. The total possible score of NEWS2 ranges from 0 to 20. A higher score indicates greater clinical risk and the need for intensive monitoring. Both groups were comparable for the use of vasopressors, antibiotic agents and glucocorticoid therapy during 

The risk of bias assessment in individual randomized controlled trials is presented in Figure 2 .

Two randomized controlled trials studies were considered of having a 'some concern' as per ROB-II tool [10] , [16] . The other studies were considered of having a 'low' risk of bias.

A total of six studies contributed to mortality data analyses. The control interventions were supportive care in 4 studies, umifenovir in 2 studies, novaferon in one stud and combined use of lopinavir-ritonavir, interferon-beta and ribavirin in 1 study. There was no significant difference J o u r n a l P r e -p r o o f in risk reduction between lopinavir-ritonavir and any of the control interventions in terms of mortality outcome (Figure 3 ). An I 2 of 0% suggested a low degree of between-trial heterogeneity. The funnel plot was asymmetrical on visual inspection (Supplementary Figure   File-Supplementary Figure 1a) . A sensitivity analysis did not affect this outcome.

A total of four studies contributed to virological cure analyses. The control interventions were supportive care in 2 studies, umifenovir in 2 studies, novaferon in one stud and combined use of novaferon and lopinavir-ritonavir in 1 study. As shown in Figure 4 , there was no significant difference between lopinavir-ritonavir and any of the control interventions in improving virological cure. An I 2 of 0% suggested a low degree of between-trial heterogeneity. The funnel plot was asymmetrical on visual inspection (Supplementary Figure File-Supplementary Figure   1b) . A sensitivity analysis did not affect this outcome.

Two studies contributed to radiological improvement analyses. The control interventions were supportive care in 1 study and umifenovir in 2 studies. As shown in Figure 5 , there was no significant difference between lopinavir-ritonavir and supportive care or umifenovir in improving virological cure. An I 2 of 83% suggested a high degree of between-trial heterogeneity among studies evaluating lopinavir-ritonavir and umifenovir.

A total of five studies contributed to adverse event data analyses. The control interventions were supportive care in 2 studies, umifenovir in 2 studies, combined use of lopinavir-ritonavir, interferon-beta and ribavirin in 1 study, novaferon in one stud and combined use of lopinavirritonavir and novaferon in 1 study. As shown in Figure 6 

The pooled meta-analytic summary indicates a search for the better drug against COVID-19

should go beyond the lopinavir-ritonavir. We observed no benefits of lopinavir-ritonavir in the treatment of COVID-19. It did not affect mortality, virological cure and radiological improvement in COVID-19 patients. A similar trend was observed in the sensitivity analysis.

We observed no difference in adverse events in patients treated with lopinavir-ritonavir as compared to control interventions.

Our findings emphasize the need to evaluate drug repurposing in the setting of randomized controlled trials before its widespread use [17] . In-vitro efficacy of Lopinavir-ritonavir against COVID-19 is not reflected in clinical studies. This could be because of a lack of reaching enough minimum effective plasma concentration of lopinavir-ritonavir against SARS-CoV-2 in COVID-19 patients. Alvarez et al observed that clinically tested dose of lopinavir-ritonavir (400 mg+100 mg) would not achieve minimum effective concentration in 50% of patients [18] . Another reason could be due to the difference in protease enzyme present in HIV and coronavirus. In the case of HIV, the protease enzyme belongs to the aspartic protease family, whereas in coronavirus protease enzyme is of the cysteine protease family. Another important difference is the catalytic site -C2 symmetry, which is only present in the HIV protease enzyme [19] . The earlier evidence of the therapeutic utility of lopinavir-ritonavir was not robust against SARS and MERS [8] . In the case of SARS, lopinavir-ritonavir was studied in two retrospective studies (one with 

Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses

Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets

A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus -A possible reference for coronavirus disease-19 treatment option

RoB 2: a revised tool for assessing risk of bias in randomised trials

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: anexploratory randomized controlled trial

Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial

Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results

SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, openlabel, parallel-group trial

Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19

Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)